European and Developing Countries Clinical Trials

Partnership (EDCTP)

Prepared by Sirpa Nuotio, Academy of Finland

EDCTP

Created in 2003 as a European Response to the

global health crisis caused by HIV/AIDS,tuberculosis and malaria

EDCTP1 in a nutshell

Number of projects: 246•259 institutions participate and receiving funds from EDCTP•3442 posts are supported on EDCTP grants•Total grant value € 382 MClinical trials: 100Training of scientists: 514Publications: 485

The second EDCTPprogramme (EDCTP2)

• EDCTP2 will operate from 2014-2024 (part of H2020)

• New legal entity EDCTP Association

• Governance: General Assembly and Board

• Offices based in the Netherlands and South Africa)

Funding

FundingFinland = 2 million €

EDCTP2: building on thecurrent programme

• Support the whole range of clinical research through broad, non-prescriptive, open calls: phase I-IV clinical trials

• Strengthen the “enabling environment” to conduct clinical research and implementation research in Africa

• Participate in large, multi-funder projects on specific activities in HIV/AIDS, TB, malaria, NIDs and implementation research on health services optimisation

• Align and partner with governments, funders and other global initiatives on PRDs for achieving an enhancing and multiplier effect

• Geographical focus on sub-Saharan Africa

EDCTP2 Participating States (current situation)

• European countries: Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Switzerland

• African countries: Congo, Cameroon, Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, Zambia

Countries that can receive funding in integrated activities

• All sub-Saharan African countries• All EU Member States and

Associated Countries

Next steps

• High-level launch of EDCTP2 on 1-3 December 2014 in Cape Town, South Africa

• 2014 Calls for proposals pre-published in October and will be open in Q4 2014

Calls

Horizon 2020 Health 2014-2015 PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: TuberculosisPHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS

More Information

• EDCTP Websitewww.edctp.org

• Academy of FinlandSirpa NuotioSirpa.nuotio@aka.fi